Banyan BioInnovations Launches as Investment Firm to Support Clinical-Stage Drug Assets, Secures Over $100M in Initial Commitments
Banyan BioInnovations, a new investment firm, has launched to support clinical-stage drug assets by forming NewCos and providing centralized development support. The firm has secured over $100 million in initial commitments from life science investors and leverages Locust Walk's global sourcing capabilities. This initiative aims to accelerate drug development and de-risk clinical milestones.
Topics: biotech investment clinical trials drug development investment firm life sciences